SEC Form 4 · accession 0001209191-16-156235
Phio Pharmaceuticals Corp. · PHIO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Pamela Pavco
Officer — Chief Development Officer
Period of report
Dec 16, 2016
Accepted (ET)
Dec 20, 2016 · 9:25 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001533040
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common stock, $0.0001 par value | Dec 16, 2016 | A | 11,111 | $0.90 | A | 17,173 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common stock warrant | $0.90 | Dec 16, 2016 | A | 11,111 | A | Dec 21, 2016 | Dec 21, 2021 | Common stock | 11,111 | 11,111 | D |